Table 1: Atorvastatin use and new onset diabetes mellitus.

Study author, yearDesignStudy locationTotal population (% F)Total population: age, mean (SD), median (range/IQR)DurationComparison groupsRisk of developing NOD (statin users vs nonstatin users)

Waters et al., 2011 [4, 22, 38, 95]3 clinical trialsTNT: worldwideTNT: 7595 (17%)TNT: 60.6 (8.9),
NA
TNT: 4.9 yearsTNT: atorvastatin 10 mg and atorvastatin 80 mgTNT: HR: 1.10 (0.94–1.29),
IDEAL: northern EuropeIDEAL: 7461 (19%)IDEAL: 61.5 (9.5), NAIDEAL: 4.8 yearsIDEAL: atorvastatin 80 mg and simvastatin 20 mgIDEAL: HR: 1.19, (0.99–1.44),
SPARCL: worldwideSPARCL: 3803 (41%)SPARCL: 62.5 (11.6), NASPARCL: 4.9 yearsSPARCL: nonstatin users and atorvastatin 80 mgSPARCL: HR: 1.34, (1.05–1.71),

Waters et al., 2013 [1, 4, 95]2 clinical trialsTNT: worldwide15,056 (18%)61.1 (9.2), NATNT: 4.9 yearsTNT: atorvastatin 10 mg and atorvastatin 80 mg0–1 risk factors:
HR: 0.97 (0.77–1.22)
IDEAL: northern Europe[TNT: 7595, IDEAL: 7461]IDEAL: 4.8 yearsIDEAL: atorvastatin 80 mg and simvastatin 20 to 40 mg2 to 4 risk factors: HR: 1.24 (1.08–1.42),

Sever et al., 2003 [26]Clinical trialUK, Ireland, Nordic countries10,305 (19%)63 (NA), NA (40–79)3.3 yearsAtorvastatin 10 mg and nonstatin usersHR: 1.15 (0.91–1.44),

Chen et al., 2013 [37]Case controlTaiwan11,715 (100%)NA, NA2 yearsAtorvastatin users and nonstatin usersAdj. OR: 2.80 (1.74–4.49),

Ma et al., 2012 [14]Retrospective cohort studyTaiwan15,637 (NA)74.9 (6.3), NA5.5 yearsAtorvastatin users and nonstatin usersAdj. HR: 0.77 (0.72–0.83),

Ma et al., 2012 [31]Retrospective cohort studyTaiwan16,027 (54%)59.9 (18.7), NA (20–84)3.5 yearsAtorvastatin users and nonstatin usersUsers vs non users:
Adj. HR: 1.29 (1.16–1.44),
Among users: Adj. HR: 1.15 (0.96–1.35),

Carter et al., 2013 [12]Retrospective cohort studyCanada471,250 (54%)NA,
73 (69–78)
12.5 yearsAtorvastatin users and pravastatin usersAll users:
Adj. HR: 1.22 (1.15–1.29)
Primary prevention users:
1.20 (1.10–1.30)
Secondary prevention users: 1.25 (1.16–1.34)

Cho et al., 2015 [35]Retrospective cohort studyKorea3680 (52.01%)NA, NA62.6 (15.3) monthsAtorvastatin users and simvastatin usersAdj. HR = 1.52(0.72–3.21),

Zaharan et al., 2013 [32]Retrospective cohort studyIreland1,235,671 (61%)NA, NA8.5 yearsAtorvastatin users and nonstatin usersAdj. HR: 1.25 (1.21–1.28),

Choe et al., 2014 [16]Cohort studyKorea394 (42%)NA, NA5 yearsAtorvastatin users and nonstatin usersAdj. HR: 3.76 (2.22–6.40),
Culver et al., 2012 [15]Cohort studyUSA153,840 (100%)63.17 (7.25)
NA (50–79)
NAAtorvastatin users and nonstatin usersAdj. HR: 1.61 (1.26–2.06)

Cederberg et al., 2015 [34]Cohort studyFinland8749 (0%)57 (7)
57 (45–73)
5.9 yearsAtorvastatin users and nonstatin usersAdj. HR: 1.21 (1.04–1.40)
Atorvastatin users (20 or 40 mg) and nonstatin usersHR: 1.37 (1.14–1.65)

Park et al., 2015 [36]Cohort studyKoreaInitial: 3566 (49.41%), after PSM adjustment: 818 (49.14%)NA, NA3 yearsAtorvastatin users (10 or 20 mg) and nonstatin usersOR: 1.99 (1.00–3.98),

Variables are expressed as absolute numbers, percentages, mean ± SD, and median (IQR). NOD: new onset diabetes mellitus; NA: not available; PSM: propensity score matching analysis; Adj. HR: adjusted hazard ratio.